Squarepoint
REGN icon

Squarepoint’s Regeneron Pharmaceuticals REGN Stock Holding History

Squarepoint’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.11M Buy
9,200
+1,900
+26% +$1.45M 0.01% 1275
2025
Q4 		$5.63M Buy
7,300
+800
+12% +$543K 0.01% 1385
2025
Q3 		$3.65M Sell
6,500
-7,100
-52% -$4.01M ﹤0.01% 1649
2025
Q2 		$7.14M Sell
13,600
-6,100
-31% -$3.4M 0.01% 1256
2025
Q1 		$12.5M Sell
19,700
-21,300
-52% -$14.7M 0.02% 923
2024
Q4 		$29.2M Buy
41,000
+25,400
+163% +$21.3M 0.03% 583
2024
Q3 		$16.4M Buy
15,600
+200
+1% +$223K 0.03% 688
2024
Q2 		$16.2M Sell
15,400
-2,800
-15% -$2.71M 0.03% 694
2024
Q1 		$17.5M Buy
18,200
+10,700
+143% +$10.2M 0.03% 675
2023
Q4 		$6.59M Buy
7,500
+4,000
+114% +$3.29M 0.01% 1215
2023
Q3 		$2.88M Sell
3,500
-800
-19% -$629K 0.01% 1542
2023
Q2 		$3.09M Buy
4,300
+700
+19% +$540K 0.01% 1376
2023
Q1 		$2.96M Sell
3,600
-5,100
-59% -$3.85M 0.01% 1172
2022
Q4 		$6.28M Buy
8,700
+400
+5% +$295K 0.02% 721
2022
Q3 		$5.72M Sell
8,300
-3,800
-31% -$2.39M 0.03% 680
2022
Q2 		$7.15M Buy
12,100
+100
+0.8% +$65K 0.04% 526
2022
Q1 		$8.38M Buy
12,000
+5,500
+85% +$3.48M 0.04% 501
2021
Q4 		$4.11M Buy
6,500
+1,200
+23% +$738K 0.01% 876
2021
Q3 		$3.21M Buy
5,300
+300
+6% +$186K 0.01% 978
2021
Q2 		$2.79M Sell
5,000
-12,800
-72% -$6.48M 0.01% 1002
2021
Q1 		$8.42M Buy
17,800
+12,800
+256% +$6.23M 0.05% 422
2020
Q4 		$2.42M Buy
+5,000
New +$2.7M 0.02% 841

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Squarepoint's REGN Position: Q1 2026 in Review

Squarepoint increased its Regeneron Pharmaceuticals (REGN) stake by 5,962% in Q1 2026, buying an estimated $123M and bringing the position to 162,814 shares worth $126M. The position accounts for 0.15% of the portfolio, ranked #118.

Squarepoint first reported a position in REGN in Q1 2016 and has held it in 32 quarters since. The position peaked at $181M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Squarepoint held 162,814 shares of Regeneron Pharmaceuticals worth $126M as of Q1 2026.
  • Squarepoint bought 160,128 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $123M.
  • Regeneron Pharmaceuticals made up 0.15% of Squarepoint's portfolio in Q1 2026, its #118 holding.
  • Squarepoint first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 32 quarters since.
  • Squarepoint's Regeneron Pharmaceuticals position peaked at $181M in Q4 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.